Anebulo Pharmaceuticals(ANEB) - 2024 Q3 - Quarterly Results

Filing Information This section provides essential identification details and filing status for Anebulo Pharmaceuticals, Inc Registrant Details This section details Anebulo Pharmaceuticals, Inc.'s core identification, incorporation, SEC filing, and stock listing | Detail | Value | | :--- | :--- | | Registrant Name | Anebulo Pharmaceuticals, Inc. | | Jurisdiction of Incorporation | Delaware | | Commission File Number | 001-40388 | | IRS Employer Identification No. | 85-1170950 | | Principal Executive Offices | 1017 Ranch Road 620 South, Suite 107 Lakeway, TX 78734 | | Telephone Number | (512) 598-0931 | | Trading Symbol | ANEB | | Exchange | Nasdaq Stock Market LLC | Filing Status Anebulo Pharmaceuticals, Inc. has indicated its status as an emerging growth company in this filing - Anebulo Pharmaceuticals, Inc. is designated as an emerging growth company[3] Item 2.02 Results of Operations and Financial Condition This section details the company's financial performance and business updates for the quarter ended March 31, 2024 Quarterly Financial Results and Business Update Anebulo Pharmaceuticals, Inc. announced Q1 2024 financial results and a business update via a May 15, 2024 press release, furnished as Exhibit 99.1 - On May 15, 2024, Anebulo Pharmaceuticals, Inc. issued a press release announcing financial results for the quarter ended March 31, 2024, and providing a business update[4] - The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K[4] - The information in this report (including Exhibit 99.1) is furnished, not deemed 'filed,' for purposes of Section 18 of the Securities Exchange Act of 1934, and is not incorporated by reference in other filings unless expressly stated[4] Item 9.01 Financial Statements and Exhibits This section lists the financial statements and exhibits included in the Form 8-K filing Exhibits This section lists the Form 8-K exhibits, including the financial results press release and interactive data file | Exhibit Number | Description | | :--- | :--- | | 99.1 | Press Release dated May 15, 2024 | | 104 | Cover Page of Interactive Data File (embedded within the Inline XBRL document) | Signatures This section provides details regarding the official signatory of the report Report Signatory The report was officially signed by Anebulo Pharmaceuticals, Inc.'s CEO, Richard Anthony Cunningham, on May 15, 2024 - The report was signed on May 15, 2024, by Richard Anthony Cunningham, Chief Executive Officer (Principal Executive Officer) of Anebulo Pharmaceuticals, Inc.[6][7]